Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01298
|
|||||
| Drug Name |
Flupentixol
|
|||||
| Synonyms |
2-[4-[(3Z)-3-[2-(Trifluoromethyl)thioxanthen-9-ylidene]propyl]piperazin-1-yl]ethanol; 4-(3-(2-(Trifluoromethyl)thioxanthen-9-ylidene)propyl)-1-piperazineethanol; 53772-82-0; ALPHA-FLUPENTHIXOL; EINECS 220-304-9; EINECS 258-756-4; Emergil; FA0UYH6QUO; FLUPENTHIXOL; Fluanxol; Flupenthixole; Flupentixol; Flupentixolum [INN-Latin]; Fluphenthixol; Fluxanxol; LC 44; N 7009; Siplaril; Siplarol; UNII-FA0UYH6QUO; cis-(Z)-Flupenthixol; cis-(Z)-Flupenthixol dihydrochloride; cis-Flupenthixol; cis-Flupentixol; flupentixolum
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Depression [ICD11: 6A8Z] | Approved | [1] | |||
| Schizophrenia [ICD11: 6A20] | Approved | [1] | ||||
| Therapeutic Class |
Antipsychotic Neuroleptic drug
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C23H25F3N2OS
|
|||||
| Canonical SMILES |
C1CN(CCN1CCC=C2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO
|
|||||
| InChI |
InChI=1S/C23H25F3N2OS/c24-23(25,26)17-7-8-22-20(16-17)18(19-4-1-2-6-21(19)30-22)5-3-9-27-10-12-28(13-11-27)14-15-29/h1-2,4-8,16,29H,3,9-15H2/b18-5-
|
|||||
| InChIKey |
NJMYODHXAKYRHW-DVZOWYKESA-N
|
|||||
| CAS Number |
CAS 2709-56-0
|
|||||
| Pharmaceutical Properties | Molecular Weight | 434.5 | Topological Polar Surface Area | 52 | ||
| Heavy Atom Count | 30 | Rotatable Bond Count | 5 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 7 | |||
| XLogP |
4.5
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
CHEBI:10454
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Flupenthixol versus placebo for schizophrenia. Cochrane Database Syst Rev. 2012 Nov 14;11:CD009777. | |||||
| 2 | Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.